WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media se ...

Core Viewpoint - Dyne Therapeutics, Inc. has announced an upsized public offering of 18,980,478 shares at a price of $18.44 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1]. Group 1: Offering Details - The public offering is expected to close around December 11, 2025, subject to customary closing conditions [1]. - Dyne has granted underwriters a 30-day option to purchase an additional 2,847,071 shares at the public offering price [1]. - Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering [2]. Group 2: Regulatory Information - The offering is made under a shelf registration statement on Form S-3 filed with the SEC on March 5, 2024, which became effective upon filing [3]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Group 3: Company Overview - Dyne Therapeutics focuses on delivering functional improvement for individuals with genetically driven neuromuscular diseases [5]. - The company is developing therapeutics targeting muscle and the central nervous system, with clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5].

Group 1 - Dyne Therapeutics, Inc. announced a public offering of 24,242,425 shares of common stock at a price of $8.25 per share, aiming for gross proceeds of $200 million before expenses [1] - The offering is expected to close around July 2, 2025, pending customary closing conditions [1] - Dyne has granted underwriters a 30-day option to purchase an additional 3,636,363 shares at the public offering price [1] Group 2 - The offering is conducted under a shelf registration statement filed with the SEC on March 5, 2024, which became effective upon filing [3] - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3] Group 3 - Dyne Therapeutics focuses on developing therapeutics for genetically driven neuromuscular diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) [5] - The company is also advancing preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [5]